Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer

NCT01957514 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01957514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01957514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer
Lead sponsor
University of Washington
Phase
Observational
Overall status
Terminated
Start date
October 28, 2013
Completion date
June 30, 2018
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative, her2/neu negative, progesterone receptor negative, stage iv breast cancer ajcc v6 and v7, triple-negative breast carcinoma